<unk>  is FDA-approved for the prevention and treatment of asthma in adults and children older than 5 years old. Like other leukotriene receptor antagonists,<unk>  is thought to be useful for the long-term treatment of asthma, but it is generally less effective than inhaled glucocorticoids as monotherapy (which are the standard of care) or long-acting beta-2 agonists in combination therapy. Notably,<unk>  is ineffective in the event of an acute asthma attack. Available forms There are two dosage forms for<unk> , notable for their age-adjustments. The 20 mg tablet is for adults and children older than age 12, whereas the 10 mg tablet is for children between the ages of 5 and 12. Tablets should be stored at room temperature, out of direct sunlight, and away from sources of moisture. Tablets are for oral administration only. Specific populations Pediatrics As a general rule, leukotriene receptor antagonists like<unk>  are more effective in children that are younger and whose asthma is less atopic. Atopy refers to a predisposition towards developing allergic conditions, including asthma, hay fever, and eczema. Geriatrics The hepatic clearance of<unk>  is impaired in adults 65 years of age and older, resulting in a 2–3 fold increase in the maximum plasma concentration and the total area under the curve.<unk>  may increase the risk for infections (7.0% vs 2.9%,<unk>  vs. placebo incidence respectively), especially lower respiratory tract infections, in older adults, though the infections noted were not severe. Pregnancy<unk>  is considered to be "pregnancy category B." This is due, in part, to the wide safety margin of<unk>  in animal studies investigating teratogenicity. No teratogenicity has been observed in doses up to 2000 mg/kg/day in cynomolgus monkeys, representing an equivalent 20x exposure of the maximum recommended daily oral dose in human adults. However, spontaneous abortions occurred in cynomolgus monkeys at 2000 mg/kg/day, though the dose itself was maternally toxic. Lactation There is limited research on the use of<unk>  in women whom are breastfeeding. Based on data from the manufacturer, it is expected that 0.6% of the maternal weight-adjusted dose would reach a breastfed infant, though the effects in the infant are unknown. Renal impairment Renal impairment does not appear to affect the pharmacokinetic profile of<unk> . Hepatic impairment The hepatic clearance of<unk>  is impaired by significant hepatic impairment. Cirrhosis of the liver can result in an increase in the maximum plasma concentration and the total area under the curve (a measure of drug exposure) by 50–60%.
Zafirlukast
Pranlukast
Seratrodast
Montelukast
Levosalbutamol
Salbutamol
Lifitegrast
Pemirolast